Official reprint from UpToDate® www.uptodate.com
©2012 UpToDate®
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use (click here) ©2012 UpToDate, Inc.
Corticosteroid therapy in septic shock
All topics are updated as new evidence becomes available and our peer review process is complete.
Literature review current through: Mar 2012. | This topic last updated: Apr 5, 2012.

INTRODUCTION — Interest in the role of glucocorticoids in the pathophysiology of critical illness has existed since the early part of the 20th century, when investigators observed that the adrenal glands are crucial to survival under conditions of physiologic stress [1,2]. The subsequent development of cortisone for clinical use was followed by clinical studies exploring the potential therapeutic role of corticosteroids in the treatment of severe infections [3-7].

The following issues are discussed in this topic review:

  • Effects of critical illness on the hypothalamic-pituitary-adrenal axis. (See 'Effects of critical illness' below.)
  • Methods of evaluating adrenal reserve (random cortisol levels, synthetic adrenocorticotropic hormone [ACTH] stimulation tests, free cortisol levels) and the impact of each on prognosis. (See 'Assessing adrenal reserve' below.)
  • The concept of relative adrenal insufficiency. (See 'Relative adrenal insufficiency' below.)
  • Clinical evidence from trials evaluating the effect of corticosteroid therapy in patients with septic shock, plus practical aspects of corticosteroid administration. (See 'Corticosteroid therapy' below.)
  • Recommendations regarding the role of corticosteroid therapy in patients with septic shock. (See 'Summary and recommendations' below.)

Other aspects of the management of severe sepsis and septic shock are reviewed separately. (See "Management of severe sepsis and septic shock in adults".)

EFFECTS OF CRITICAL ILLNESS — The hypothalamus continuously integrates stimuli and secretes corticotropin releasing hormone (CRH) whenever homeostasis is threatened. CRH stimulates the release of adrenocorticotropic hormone (ACTH) from the anterior pituitary, which induces cortisol secretion from the adrenal glands. Cortisol is the effector molecule of the hypothalamic-pituitary-adrenal (HPA) axis.

Activation of the HPA axis — Normal serum cortisol levels range between 5 and 24 mcg/dL, with significant variability depending upon the time of day [8]. The HPA axis is activated and diurnal variation is lost during physiological stress (eg, major surgery, hypotension, severe infection) [9,10]. Serum cortisol increases as a result, reaching levels as high as 40 to 50 mcg/dL (figure 1) [9,11-14].

In addition to activation of the HPA axis by physiological stress, cortisol metabolism and function may be considerably altered by other aspects of critical illness:

  • Renal dysfunction may prolong the half-life of circulating cortisol.
  • Plasma concentrations of both cortisol binding globulin (CBG) and albumin, which bind >90 percent of circulating cortisol under normal circumstances, are frequently diminished. This results in an increase in the free cortisol, which is believed to be the physiologically active form of the hormone [11,15,16].
  • Inflammatory cytokines may increase glucocorticoid receptor affinity, disable glucocorticoid inactivation, and/or increase the peripheral conversion of precursors to cortisol [11,17,18].

Impairment of the HPA axis — There are circumstances in which cortisol availability cannot be increased sufficiently to meet demand. As an example, drugs like ketoconazole, phenytoin, and etomidate may impair cortisol synthesis [11,19,20]. An observational study of 62 patients found that the use of etomidate for intubation was associated with increased likelihood of having a poor response (≤9 mcg/dL) to ACTH stimulation 24 hours later (odds ratio 12, 95% CI 3-50) [21].

The clinical importance of this observation is uncertain. While some evidence suggests that a single dose of etomidate is associated with worse outcomes in patients with septic shock [22], a randomized trial that compared etomidate with ketamine for rapid sequence induction found that etomidate was NOT associated with worse clinical outcomes despite an increased incidence of adrenocortical hyporesponsiveness to synthetic adrenocorticotropic hormone (ACTH) [23]. The clinical implications of these findings are uncertain because both studies measured plasma cortisol using an immunoassay, which correlates poorly with the reference standard (liquid chromatography with mass spectroscopy) [24].

Head injury, central nervous system depressants, pituitary infarction, adrenal hemorrhage, infections, malignancy, and previous corticosteroid therapy can also impair the HPA axis [11]. Sometimes an etiology cannot be identified.

ASSESSING ADRENAL RESERVE

Random serum cortisol — Serum cortisol levels vary widely in patients with septic shock [14,25-30]. This observation led multiple investigators to try to determine whether serum cortisol is predictive of mortality in patients with septic shock. Numerous studies found increased mortality associated with both low serum cortisol levels and high serum cortisol levels [31-36]. Other studies were unable to find a relationship between cortisol levels and mortality [26,28,37].

ACTH stimulation tests — An adrenocorticotropic hormone (ACTH) stimulation test requires that a baseline serum cortisol be drawn and then synthetic ACTH (cosyntropin) administered intravenously. Serum cortisol levels are drawn 30 and 60 minutes later.

There are two types of ACTH stimulation tests. A high-dose ACTH stimulation test involves the administration of 250 mcg of synthetic ACTH. In contrast, a low-dose ACTH stimulation test involves the administration of only 1 mcg of synthetic ACTH.

High-dose ACTH test — Studies using a high-dose ACTH stimulation test have yielded variable results in septic shock [26,29,37-39]. A prospective cohort study performed high-dose ACTH stimulation tests on 189 patients with septic shock [39]. The results correlated with 28-day mortality: a baseline serum cortisol level >34 mcg/dL and a maximum increase in cortisol of ≤9 mcg/dL were identified as risk factors for death. Three prognostic groups were proposed:

  • Good prognosis (26 percent mortality): Baseline plasma cortisol ≤34 mcg/dL and a cortisol increase >9 mcg/dL in response to cosyntropin.
  • Poor prognosis (82 percent mortality): Baseline plasma cortisol >34 mcg/dL and a cortisol increase ≤9 mcg/dL in response to cosyntropin.
  • Intermediate prognosis (67 percent mortality): Baseline plasma cortisol >34 mcg/dL and a cortisol increase >9 mcg/dL in response to cosyntropin, or baseline plasma cortisol ≤34 mcg/dL and a cortisol increase ≤9 mcg/dL in response to cosyntropin.

The results from this study are supported by a more recent and larger retrospective cohort study, in which 477 patients with severe sepsis or septic shock underwent high-dose ACTH testing [40]. Nonsurvivors had a higher baseline cortisol level (30 versus 24 mcg/dL) and a smaller cortisol increase (6 versus 11 mcg/dL) than survivors. Patients with either a baseline cortisol level <15 mcg/dL or a cortisol increase ≤9 mcg/dL had a higher mortality, longer duration of shock, or shorter survival time.

Low-dose ACTH test — Some investigators believe that 250 mcg of cosyntropin is supraphysiologic and stimulates adrenal secretion of cortisol even when adrenal dysfunction exists, noting that even patients with impaired adrenal reserve can mount an apparently normal adrenal response to such a high dose of cosyntropin. Use of low-dose (1 mcg) cosyntropin has been proposed as an alternative [41]. (See "Evaluation of the response to ACTH in adrenal insufficiency", section on 'Low-dose ACTH stimulation test'.)

Two investigations have compared a low-dose (1 mcg) ACTH stimulation test to a high-dose (250 mcg) ACTH stimulation test [42,43].

The first study was a prospective cohort study of 59 patients with septic shock who were sequentially administered 1 mcg and 250 mcg of cosyntropin intravenously [42]. All of the patients then received hydrocortisone 100 mg intravenously every eight hours. Patients were designated as steroid responsive if they were able to maintain a mean arterial blood pressure >65 mmHg without norepinephrine infusion within 24 hours after starting hydrocortisone:

  • Adrenal insufficiency (defined as post-cosyntropin serum cortisol of <18 mcg/dL) was detected in more patients by low-dose ACTH testing than high-dose ACTH testing (22 versus 8 percent).
  • 54 percent of steroid responders had a diagnostic low-dose ACTH stimulation test, while 22 percent had a diagnostic high-dose ACTH stimulation test. This suggests that adrenal insufficiency detected by low-dose ACTH stimulation was superior to that detected by high-dose ACTH stimulation in predicting hemodynamic responsiveness to corticosteroids.
  • Retrospective evaluation demonstrated that a random serum cortisol level <25 mcg/dL was the most accurate diagnostic threshold, predicting steroid responsiveness in 96 percent of the subjects.

The second study was similar, administering low-dose (1 mcg) and high-dose (250 mcg) cosyntropin consecutively to 46 patients with septic shock [43]. Serum cortisol levels were measured at baseline and after each stimulation test. A positive response to ACTH stimulation was defined as a serum cortisol increase >9 mcg/dL. Patients who responded to low-dose and high-dose ACTH were more likely to survive than those who did not respond to either dose. In addition, a response only to high-dose ACTH stimulation was associated with lower survival than a response to both low-dose and high-dose ACTH stimulation, suggesting that low-dose ACTH stimulation identified a subgroup of patients with inadequate adrenal reserve that would have been missed by high-dose ACTH stimulation alone.

Larger studies are needed before the significance of the findings from these two investigations can be fully understood.

Limitations — ACTH stimulation tests may be unreliable in critically ill patients for several reasons:

  • Some critically ill individuals have spontaneous increases in their serum cortisol of ≥9 mcg/dL WITHOUT cosyntropin stimulation [44]. Thus, this threshold may not be clinically helpful.
  • ACTH stimulation tests may give inconsistent results in the same individuals if performed on more than one occasion [26,45].
  • Most clinical laboratories use immunoassays to measure the total cortisol because the reference standard, liquid chromatography-tandem mass spectrometry (LC-MS/MS), is a time- and labor-intensive assay that is not available in most centers [46]. However, immunoassays appear to correlate poorly with LC-MS/MS during septic shock. This was illustrated by a study of 425 ACTH stimulation tests (850 cortisol samples) that found that approximately 27 percent of the samples were incorrectly classified by immunoassays [47].

Free cortisol — In critically ill patients, loss of cortisol binding globulin (CBG) results in decreased protein-bound cortisol and increased free cortisol. Therefore, for any given amount of serum total cortisol, there is a shift from inactive protein-bound cortisol to physiologically active free cortisol. This suggests that standard assays for plasma cortisol (which measure total plasma cortisol) underestimate HPA axis activity. It has been proposed that free cortisol more accurately reflects HPA axis activation [48].

This was illustrated by a study comparing total serum cortisol and free serum cortisol levels in 33 healthy volunteers to those in 60 critically ill patients (18 had sepsis) [48]. The critically ill patients had total serum cortisol concentrations that were two to three times higher and free cortisol levels that were 7 to 10 times higher than healthy volunteers. Although the total serum cortisol appeared lower in critically ill patients with hypoalbuminemia (albumin ≤2.5 g/dL) than in critically ill patients with preserved albumin concentrations, the free cortisol levels were similar.

The study has two major limitations. First, the critically ill patients did not include any patients with septic shock [49]. Second, the degree of hemodynamic instability at the time of plasma cortisol sampling was not reported. Thus, it is impossible to correlate the cortisol level with severity of illness or physiologic status [50]. The applicability of the study to routine clinical practice is uncertain because the free cortisol assay is not available at most clinical centers [51].

In another investigation, 74 patients had their total and free cortisol levels measured before and after the administration of 250 mcg of cosyntropin [52]:

  • Pre-stimulation free cortisol levels were higher in patients with septic shock (186 nmol/L) than sepsis (29 nmol/L) or healthy controls (13 nmol/L).
  • Pre-stimulation free cortisol levels reflected the severity of illness more closely than total cortisol levels.
  • The calculated free cortisol level (based on direct measurements of total cortisol and the CBG concentration) correlated well with the direct measurement of free cortisol.

Whether the free cortisol level provides useful prognostic information in critically ill patients has not been formally investigated.

RELATIVE ADRENAL INSUFFICIENCY — Cortisol is necessary to survive critical illness [1,2]. But, how much is enough?

Absolute adrenal insufficiency is rare among critically ill patients, with an incidence estimated to be ≤3 percent [53]. However, the following observations argue that suboptimal cortisol production may be common and associated with worse outcomes:

  • A maximum increase of serum cortisol ≤9 mcg/dL following intravenous synthetic adrenocorticotropic hormone (ACTH) stimulation is associated with increased mortality from septic shock [39,43].
  • Baseline and post-ACTH serum cortisol <23.7 mcg/dL predict responsiveness to exogenous steroids in septic shock, where responsiveness is defined by the ability to maintain a mean arterial blood pressure >65 mmHg without norepinephrine infusion within 24 hours after starting hydrocortisone [42].

Suboptimal cortisol production during septic shock has been termed "functional" or "relative" adrenal insufficiency [11]. This condition has also been called “critical illness-related corticosteroid insufficiency (CIRCI)” [54]. There is no consensus about the diagnostic criteria or indications for treatment of this entity. In addition, there exists considerable disagreement over what cortisol level is "normal" or "appropriate" in septic shock, what constitutes an adequate response to ACTH, and what dose of synthetic ACTH should be used for stimulation testing.

The question of how much cortisol is enough for a critically ill patient is confounded by the possibility that glucocorticoid resistance exists at the target-tissue level. Few data support the notion that genetic or acquired glucocorticoid receptor abnormalities affect critically ill patients. Assays of the cellular activity of cortisol, cortisol-glucocorticoid-receptor binding, and glucocorticoid-receptor transcription activity are limited to experimental investigations and their clinical relevance is unknown [55]. The mechanisms of glucocorticoid resistance are discussed separately. (See "Glucocorticoid-resistant asthma", section on 'Mechanisms of glucocorticoid resistance'.)

Using an overnight metyrapone stimulation test as the reference standard, a prospective cohort study found that patients with septic shock who had a baseline total cortisol level <10 mcg/dL or a change in total cortisol <9 mcg/dL after high-dose ACTH stimulation, were likely to have adrenal insufficiency [56]. Conversely, patients with septic shock who had a baseline total cortisol level ≥44 mcg/dL or a change in total cortisol ≥16.8 mcg/dL, were unlikely to have adrenal insufficiency. The generalizability of these results has been questioned because the frequency of absolute adrenal insufficiency in this study was nearly four times that previously reported [57]. In addition, the values were not used to guide therapeutic decision making and, therefore, their impact on clinical outcome is unknown.

We believe that it is uncertain whether "relative adrenal insufficiency" or a synonymous condition is a true diagnostic entity, since a clear definition is lacking and the cortisol assays that are available at most clinical laboratories are unreliable in the critically ill patient.

CORTICOSTEROID THERAPY — Interest in the possible therapeutic role of corticosteroids in severe infections has existed for at least 50 years [4-7,58,59].

Clinical evidence — In the 1980s, three randomized, double-blind, placebo-controlled studies were published [60-62]. None of the trials found a mortality benefit and only one trial noted decreased duration to shock resolution associated with the administration of corticosteroids. All of the trials administered high-dose corticosteroids for a short duration and used early endpoints.

In the 1990s, interest in corticosteroids as a therapy in septic shock was renewed, this time using smaller, more physiological doses for longer duration. Three small trials (approximately 40 patients each) compared corticosteroid administration to placebo in patients with septic shock and found decreased duration of shock associated with corticosteroid therapy [63-65]. These trials prompted larger randomized trials.

French trial — In a multicenter, double-blind trial conducted in France, 300 patients were randomly assigned to receive placebo or hydrocortisone (50 mg intravenously every six hours) plus fludrocortisone (50 mcg enterally once a day) within eight hours of the onset of septic shock [66]. Treatment continued for seven days. Based upon a high-dose (250 mcg) ACTH stimulation test, the patients were classified as having adequate adrenal reserve (maximum increase in serum cortisol of >9 mcg/dL) or inadequate adrenal reserve (maximum cortisol increase of ≤9 mcg/dL):

  • Among all patients, hydrocortisone administration decreased 28-day mortality (55 versus 61 percent)
  • Among patients defined as having inadequate adrenal reserve, hydrocortisone administration decreased 28-day mortality (53 versus 63 percent), ICU mortality (58 versus 70 percent), and hospital mortality (61 versus 72 percent), as well as more vasopressor withdrawal (57 versus 40 percent)
  • Among patients defined as having adequate adrenal reserve, there was no difference in mortality or vasopressor withdrawal

The trial was criticized for its high placebo-group mortality and the statistical methods used to describe outcomes [67-69].

The association between corticosteroid therapy and improved mortality was supported by two subsequent meta-analyses [70,71]. However, no significant benefit was noted in a large randomized trial (CORTICUS) published after the meta-analyses.

CORTICUS — The Corticosteroid Therapy of Septic Shock (CORTICUS) trial was a multicenter, double-blind trial that randomly assigned 499 patients with septic shock to receive hydrocortisone (50 mg) or placebo intravenously every six hours for five days, followed by a tapering regimen [72]. Based upon a high-dose (250 mcg) ACTH stimulation test, the patients were classified as having inadequate adrenal reserve (maximum cortisol increase of ≤9 mcg/dL) or adequate adrenal reserve (maximum increase in serum cortisol of >9 mcg/dL).

Hydrocortisone administration did not improve 28-day mortality (35 versus 32 percent in the placebo group). This was also true in the two pre-defined subgroups – patients with inadequate adrenal reserve and patients with adequate adrenal reserve. The hydrocortisone group had faster reversal of shock among all patients (3.3 versus 5.8 days in the placebo group) and increased incidence of new infection that did not reach statistical significance (odds ratio 1.27, 95% CI 0.96-1.68). The trial was criticized for the lower than expected placebo-group mortality (32 percent versus the anticipated 50 percent).

Comparison — These randomized trials have important differences that may, at least in part, explain their conflicting results.

  • The French trial enrolled patients within eight hours after the onset of shock and included patients with a greater severity of illness [66]. The mean Simplified Acute Physiology Score II (SAPS II) was 55.5 and septic shock was defined as a systolic blood pressure <90 mmHg for more than one hour despite adequate fluid resuscitation and vasopressor administration.
  • The CORTICUS trial enrolled patients within 72 hours of the onset of shock and included patients with a lower severity of illness [72]. The mean SAPS II was 49 and septic shock was defined as a systolic blood pressure <90 mmHg despite adequate fluid resuscitation, or the need for vasopressor administration for more than one hour.

These differences imply that corticosteroid therapy is most likely to benefit patients with severe septic shock. This was supported by two meta-analyses that looked at the effects of long courses of low-dose steroids (≤300 mg per day of hydrocortisone or an equivalent for ≥5 days) in patients with septic shock:

  • A meta-analysis of 12 randomized and quasi-randomized trials (1228 patients) found that corticosteroid treatment decreased mortality compared to placebo or supportive care (38 versus 44 percent, relative risk 0.84, 95% CI 0.72-0.97) [73]. A meta-regression analysis found a significant association between the severity of illness and the effect of corticosteroids on mortality [74].
  • Similarly, a meta-analysis of 12 randomized trials (1171 patients) found that corticosteroid treatment decreased mortality compared to placebo or supportive care (38 versus 44 percent, odds ratio 0.64, 95% CI 0.45-0.93) [75]. A meta-regression analysis found that more severely ill patients were more likely to benefit from corticosteroid therapy and that corticosteroid therapy was more harmful in less severely ill patients [76].

Both meta-analyses detected possible publication bias and the latter meta-analyses had a moderate amount of heterogeneity, limiting our confidence in the estimate of the effect.

Conclusions — Several conclusions can be based upon the available evidence:

  • Corticosteroid therapy is most likely to be beneficial to patients who have severe septic shock (which we define as a systolic blood pressure <90 mmHg for more than one hour despite adequate fluid resuscitation and vasopressor administration), especially if begun within eight hours of the onset of shock.
  • There are no high or moderate quality data to suggest that corticosteroid therapy is beneficial to patients with less severe septic shock.
  • Laboratory assays of plasma cortisol concentration may be unreliable in critically ill patients and fail to identify patients who are more likely to benefit from corticosteroid therapy. (See 'High-dose ACTH test' above.)

Administration — Hydrocortisone is a pharmacologic form of cortisol. Compared to hydrocortisone, other pharmacologic corticosteroids bind cortisol-binding globulin (CBG) poorly, resulting in more free, physiologically active corticosteroid and greater potency at any given dose. The different preparations vary widely in anti-inflammatory and mineralocorticoid potency.

Most studies evaluating the effect of corticosteroids in septic shock used hydrocortisone, although administration protocols and treatment durations varied. It is unknown whether the findings can be generalized to other synthetic corticosteroids. We typically administer 50 mg of hydrocortisone every six hours or 100 mg of hydrocortisone every eight hours.

There is no consensus regarding the optimal administration protocol or treatment duration, because no study has compared fixed-duration regimens to clinically-guided regimens, or tapering to abrupt cessation [77]. However, in one clinical study, abrupt cessation was associated with rebound of hemodynamic abnormalities and increased inflammatory markers [78].

Although one of the large randomized trials added fludrocortisone at a dose of 50 mcg per day for seven days, we do not typically add fludrocortisone because we believe that hydrocortisone alone has sufficient mineralocorticoid effect and absorption of the enterally administered drug is questionable in situations of compromised splanchnic perfusion [66]. Our decision to forego fludrocortisone is supported by a trial (the Corticosteroids and Intensive Insulin Therapy for Septic Shock [COIITSS] trial) that randomly assigned 509 patients with septic shock to receive either hydrocortisone plus fludrocortisone or hydrocortisone alone [79]. There was no difference in any of the clinical outcomes.

SUMMARY AND RECOMMENDATIONS

Summary

  • Clinically available tests that measure plasma cortisol are likely unreliable in critically ill patients. (See 'Assessing adrenal reserve' above.)
  • High-dose (250 mcg) synthetic adrenocorticotropic hormone (ACTH) stimulation may separate patients with septic shock into different prognostic groups. However, the unreliability of available plasma cortisol assays make the clinical usefulness of this test doubtful. (See 'High-dose ACTH test' above.)
  • Suboptimal cortisol production during septic shock has been termed "functional" adrenal insufficiency, "relative" adrenal insufficiency, or “critical illness-related corticosteroid insufficiency (CIRCI)”. Broadly accepted consensus about diagnostic criteria for this entity is lacking. (See 'Relative adrenal insufficiency' above.)
  • Corticosteroid therapy may be beneficial to patients who have severe septic shock (defined as a systolic blood pressure <90 mmHg for more than one hour despite adequate fluid resuscitation plus vasopressor administration), especially if begun within eight hours of the onset of shock. (See 'Clinical evidence' above.)
  • There are no high or moderate quality data to suggest that corticosteroid therapy is beneficial to patients with less severe septic shock. (See 'Clinical evidence' above.)
  • Classification of adrenal reserve as adequate or inadequate fails to identify patients who are more likely to benefit from corticosteroid therapy. (See 'Clinical evidence' above.)

Recommendations

  • For patients with severe septic shock (defined as a systolic blood pressure <90 mmHg for more than one hour despite both adequate fluid resuscitation and vasopressor administration), we suggest initiation of intravenous corticosteroid therapy within eight hours after the onset of shock (Grade 2B). Response to ACTH testing should not be used to select patients for corticosteroid therapy. (See 'Clinical evidence' above.)
  • We suggest that corticosteroids be administered for five to seven days (Grade 2C). A tapering course is optional; however, close observation of those patients whose steroid therapy is stopped without being tapered is warranted. (See 'Administration' above.)
  • We suggest that fludrocortisone NOT be added to the corticosteroid regimen (Grade 2C). (See 'Administration' above.)

Use of UpToDate is subject to the Subscription and License Agreement.

REFERENCES

  1. Scott WJ. THE INFLUENCE OF THE ADRENAL GLANDS ON RESISTANCE : II. THE TOXIC EFFECT OF KILLED BACTERIA IN ADRENALECTOMIZED RATS. J Exp Med 1924; 39:457.
  2. Seyle, H. A syndrome produced by diverse nocuous agents. Nature 1936; 138:32.
  3. HENCH PS, SLOCUMB CH, POLLEY HF, KENDAL EC. Effect of cortisone and pituitary adrenocorticotropic hormone (ACTH) on rheumatic diseases. J Am Med Assoc 1950; 144:1327.
  4. SPINK WW. ACTH and adrenocorticosteroids as therapeutic adjuncts in infectious diseases. N Engl J Med 1957; 257:1031.
  5. WAGNER HN Jr, BENNETT IL Jr, LASAGNA L, et al. The effect of hydrocortisone upon the course of pneumococcal pneumonia treated with penicillin. Bull Johns Hopkins Hosp 1956; 98:197.
  6. KASS EH. Adrenocorticosteroids and the management of infectious diseases. AMA Arch Intern Med 1958; 102:1.
  7. Bennett, IL Jr, Finland, M, Hamburger, M. The effectiveness of hydrocortisone in the management of severe infections. JAMA 1963; 183:462.
  8. Stewart PM. The Adrenal Cortex. In: Williams Textbook of Endocrinology, Polonsky KS (Ed), Saunders, Philadelphia 2002. p.491.
  9. Lamberts SW, Bruining HA, de Jong FH. Corticosteroid therapy in severe illness. N Engl J Med 1997; 337:1285.
  10. Shenker Y, Skatrud JB. Adrenal insufficiency in critically ill patients. Am J Respir Crit Care Med 2001; 163:1520.
  11. Cooper MS, Stewart PM. Corticosteroid insufficiency in acutely ill patients. N Engl J Med 2003; 348:727.
  12. Newsome HH, Rose JC. The response of human adrenocorticotrophic hormone and growth hormone to surgical stress. J Clin Endocrinol Metab 1971; 33:481.
  13. HUME DM, BELL CC, BARTTER F. Direct measurement of adrenal secretion during operative trauma and convalescence. Surgery 1962; 52:174.
  14. Vadas P, Pruzanski W. Plasma cortisol levels in patients with septic shock. Crit Care Med 1991; 19:300.
  15. Beishuizen A, Thijs LG, Vermes I. Patterns of corticosteroid-binding globulin and the free cortisol index during septic shock and multitrauma. Intensive Care Med 2001; 27:1584.
  16. Hammond GL, Smith CL, Paterson NA, Sibbald WJ. A role for corticosteroid-binding globulin in delivery of cortisol to activated neutrophils. J Clin Endocrinol Metab 1990; 71:34.
  17. Cooper MS, Bujalska I, Rabbitt E, et al. Modulation of 11beta-hydroxysteroid dehydrogenase isozymes by proinflammatory cytokines in osteoblasts: an autocrine switch from glucocorticoid inactivation to activation. J Bone Miner Res 2001; 16:1037.
  18. Franchimont D, Martens H, Hagelstein MT, et al. Tumor necrosis factor alpha decreases, and interleukin-10 increases, the sensitivity of human monocytes to dexamethasone: potential regulation of the glucocorticoid receptor. J Clin Endocrinol Metab 1999; 84:2834.
  19. WERK EE Jr, MACGEE J, SHOLITON LJ. EFFECT OF DIPHENYLHYDANTOIN ON CORTISOL METABOLISM IN MAN. J Clin Invest 1964; 43:1824.
  20. Ledingham IM, Watt I. Influence of sedation on mortality in critically ill multiple trauma patients. Lancet 1983; 1:1270.
  21. Malerba G, Romano-Girard F, Cravoisy A, et al. Risk factors of relative adrenocortical deficiency in intensive care patients needing mechanical ventilation. Intensive Care Med 2005; 31:388.
  22. Cuthbertson BH, Sprung CL, Annane D, et al. The effects of etomidate on adrenal responsiveness and mortality in patients with septic shock. Intensive Care Med 2009; 35:1868.
  23. Jabre P, Combes X, Lapostolle F, et al. Etomidate versus ketamine for rapid sequence intubation in acutely ill patients: a multicentre randomised controlled trial. Lancet 2009; 374:293.
  24. Kaufman D. Etomidate versus ketamine for sedation in acutely ill patients. Lancet 2009; 374:1240.
  25. MELBY JC, SPINK WW. Comparative studies on adrenal cortical function and cortisol metabolism in healthy adults and in patients with shock due to infection. J Clin Invest 1958; 37:1791.
  26. Bouachour G, Roy PM, Guiraud MP. The repetitive short corticotropin stimulation test in patients with septic shock. Ann Intern Med 1995; 123:962.
  27. Sibbald WJ, Short A, Cohen MP, Wilson RF. Variations in adrenocortical responsiveness during severe bacterial infections. Unrecognized adrenocortical insufficiency in severe bacterial infections. Ann Surg 1977; 186:29.
  28. Schein RM, Sprung CL, Marcial E, et al. Plasma cortisol levels in patients with septic shock. Crit Care Med 1990; 18:259.
  29. Moran JL, Chapman MJ, O'Fathartaigh MS, et al. Hypocortisolaemia and adrenocortical responsiveness at onset of septic shock. Intensive Care Med 1994; 20:489.
  30. Briegel J, Schelling G, Haller M, et al. A comparison of the adrenocortical response during septic shock and after complete recovery. Intensive Care Med 1996; 22:894.
  31. McKee JI, Finlay WE. Cortisol replacement in severely stressed patients. Lancet 1983; 1:484.
  32. Jurney TH, Cockrell JL Jr, Lindberg JS, et al. Spectrum of serum cortisol response to ACTH in ICU patients. Correlation with degree of illness and mortality. Chest 1987; 92:292.
  33. Span LF, Hermus AR, Bartelink AK, et al. Adrenocortical function: an indicator of severity of disease and survival in chronic critically ill patients. Intensive Care Med 1992; 18:93.
  34. Jarek MJ, Legare EJ, McDermott MT, et al. Endocrine profiles for outcome prediction from the intensive care unit. Crit Care Med 1993; 21:543.
  35. Drucker D, Shandling M. Variable adrenocortical function in acute medical illness. Crit Care Med 1985; 13:477.
  36. Rothwell PM, Lawler PG. Prediction of outcome in intensive care patients using endocrine parameters. Crit Care Med 1995; 23:78.
  37. Rothwell PM, Udwadia ZF, Lawler PG. Cortisol response to corticotropin and survival in septic shock. Lancet 1991; 337:582.
  38. Bouachour G, Tirot P, Gouello JP, et al. Adrenocortical function during septic shock. Intensive Care Med 1995; 21:57.
  39. Annane D, Sébille V, Troché G, et al. A 3-level prognostic classification in septic shock based on cortisol levels and cortisol response to corticotropin. JAMA 2000; 283:1038.
  40. Lipiner-Friedman D, Sprung CL, Laterre PF, et al. Adrenal function in sepsis: the retrospective Corticus cohort study. Crit Care Med 2007; 35:1012.
  41. Marik P, Zaloga G. Prognostic value of cortisol response in septic shock. JAMA 2000; 284:308.
  42. Marik PE, Zaloga GP. Adrenal insufficiency during septic shock. Crit Care Med 2003; 31:141.
  43. Siraux V, De Backer D, Yalavatti G, et al. Relative adrenal insufficiency in patients with septic shock: comparison of low-dose and conventional corticotropin tests. Crit Care Med 2005; 33:2479.
  44. Venkatesh B, Mortimer RH, Couchman B, Hall J. Evaluation of random plasma cortisol and the low dose corticotropin test as indicators of adrenal secretory capacity in critically ill patients: a prospective study. Anaesth Intensive Care 2005; 33:201.
  45. Loisa P, Uusaro A, Ruokonen E. A single adrenocorticotropic hormone stimulation test does not reveal adrenal insufficiency in septic shock. Anesth Analg 2005; 101:1792.
  46. Bornstein SR. Predisposing factors for adrenal insufficiency. N Engl J Med 2009; 360:2328.
  47. Briegel J, Sprung CL, Annane D, et al. Multicenter comparison of cortisol as measured by different methods in samples of patients with septic shock. Intensive Care Med 2009; 35:2151.
  48. Hamrahian AH, Oseni TS, Arafah BM. Measurements of serum free cortisol in critically ill patients. N Engl J Med 2004; 350:1629.
  49. Polderman KH, van Zanten A, Girbes AR. Free cortisol and critically ill patients. N Engl J Med 2004; 351:395.
  50. Dubey A, Boujoukos AJ. Measurements of serum free cortisol in critically ill patients. Crit Care 2005; 9:E2.
  51. Khan T, Kupfer Y, Tessler S. Free cortisol and critically ill patients. N Engl J Med 2004; 351:395.
  52. Ho JT, Al-Musalhi H, Chapman MJ, et al. Septic shock and sepsis: a comparison of total and free plasma cortisol levels. J Clin Endocrinol Metab 2006; 91:105.
  53. Burry LD, Wax RS. Role of corticosteroids in septic shock. Ann Pharmacother 2004; 38:464.
  54. Marik PE, Pastores SM, Annane D, et al. Recommendations for the diagnosis and management of corticosteroid insufficiency in critically ill adult patients: consensus statements from an international task force by the American College of Critical Care Medicine. Crit Care Med 2008; 36:1937.
  55. Peeters RP, Hagendorf A, Vanhorebeek I, et al. Tissue mRNA expression of the glucocorticoid receptor and its splice variants in fatal critical illness. Clin Endocrinol (Oxf) 2009; 71:145.
  56. Annane D, Maxime V, Ibrahim F, et al. Diagnosis of adrenal insufficiency in severe sepsis and septic shock. Am J Respir Crit Care Med 2006; 174:1319.
  57. Meyer NJ, Hall JB. Relative adrenal insufficiency in the ICU: can we at least make the diagnosis? Am J Respir Crit Care Med 2006; 174:1282.
  58. Schumer W. Steroids in the treatment of clinical septic shock. Ann Surg 1976; 184:333.
  59. Shine KI, Kuhn M, Young LS, Tillisch JH. Aspects of the management of shock. Ann Intern Med 1980; 93:723.
  60. Sprung CL, Caralis PV, Marcial EH, et al. The effects of high-dose corticosteroids in patients with septic shock. A prospective, controlled study. N Engl J Med 1984; 311:1137.
  61. Bone RC, Fisher CJ Jr, Clemmer TP, et al. A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med 1987; 317:653.
  62. Effect of high-dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis. The Veterans Administration Systemic Sepsis Cooperative Study Group. N Engl J Med 1987; 317:659.
  63. Bollaert PE, Charpentier C, Levy B, et al. Reversal of late septic shock with supraphysiologic doses of hydrocortisone. Crit Care Med 1998; 26:645.
  64. Briegel J, Forst H, Haller M, et al. Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double-blind, single-center study. Crit Care Med 1999; 27:723.
  65. Yildiz O, Doganay M, Aygen B, et al. Physiological-dose steroid therapy in sepsis [ISRCTN36253388]. Crit Care 2002; 6:251.
  66. Annane D, Sébille V, Charpentier C, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002; 288:862.
  67. Beigel J, Eichacker P. Hydrocortisone and fludrocortisone improved 28-day survival in septic shock and adrenal insufficiency. ACP J Club 2003; 138:44.
  68. Rubenfeld, GD. When survival is not the same as mortality. Critical Care Alert 2003; 10:113.
  69. Eisen LA. Epoetin alfa in critically ill patients. N Engl J Med 2007; 357:2516; author reply 2516.
  70. Annane D, Bellissant E, Bollaert PE, et al. Corticosteroids for treating severe sepsis and septic shock. Cochrane Database Syst Rev 2004; :CD002243.
  71. Minneci PC, Deans KJ, Banks SM, et al. Meta-analysis: the effect of steroids on survival and shock during sepsis depends on the dose. Ann Intern Med 2004; 141:47.
  72. Sprung CL, Annane D, Keh D, et al. Hydrocortisone therapy for patients with septic shock. N Engl J Med 2008; 358:111.
  73. Annane D, Bellissant E, Bollaert PE, et al. Corticosteroids in the treatment of severe sepsis and septic shock in adults: a systematic review. JAMA 2009; 301:2362.
  74. Minneci PC, Deans KJ, Natanson C. Corticosteroid therapy for severe sepsis and septic shock. JAMA 2009; 302:1643; author reply 1644.
  75. Minneci PC, Deans KJ, Eichacker PQ, Natanson C. The effects of steroids during sepsis depend on dose and severity of illness: an updated meta-analysis. Clin Microbiol Infect 2009; 15:308.
  76. Minneci PC, Deans KJ, Natanson C. Corticosteroid therapy for severe sepsis and septic shock. JAMA 2009; 302:1643; author reply 1644.
  77. Dellinger RP, Levy MM, Carlet JM, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008; 36:296.
  78. Keh D, Boehnke T, Weber-Cartens S, et al. Immunologic and hemodynamic effects of "low-dose" hydrocortisone in septic shock: a double-blind, randomized, placebo-controlled, crossover study. Am J Respir Crit Care Med 2003; 167:512.
  79. COIITSS Study Investigators, Annane D, Cariou A, et al. Corticosteroid treatment and intensive insulin therapy for septic shock in adults: a randomized controlled trial. JAMA 2010; 303:341.
Topic 1654 Version 6.0

All topics are updated as new information becomes available. Our peer review process typically takes one to six weeks depending on the issue.